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Background: Efficacy of PO cobalamin (Cbl) supplementation in dogs with hereditary Cbl malab-
sorption (Imerslund-Gräsbeck syndrome, IGS) is unknown.
Objectives: To evaluate PO Cbl supplementation in Beagles with IGS previously treated paren-
terally. We hypothesized that 1 mg cyano-Cbl daily PO would maintain clinical and metabolic
remission.
Animals: Three client-owned Beagles with IGS and 48 healthy control dogs.
Methods: Prospective study. Daily PO cyanocobalamin (cyano-Cbl; 1 mg) supplementation was
monitored for 13 (2 dogs) and 8 months (1 dog). Health status was assessed by owner observa-
tions. Methylmalonic acid (MMA)-to-creatinine concentrations were measured using an ultra-
performance liquid chromatography-tandem mass spectrometry (UPLC-TMS) method on urine
samples collected monthly. Concurrent measurements of serum MMA concentration (n = 7;
UPLC-TMS) were available for 1 dog.
Results: All dogs remained in excellent health during PO supplementation. Urine MMA remained
consistently low in 2 dogs (median, 2.5 mmol/mol creatinine; range, 1.2-9; healthy dogs [n = 30],
median, 2.9 mmol/mol creatinine; range, 1.3-76.5). Urine MMA ranged from 38.9-84.9 mmol/mol
creatinine during the first 6 months in 1 dog already known to excrete comparable amounts when
supplemented parenterally. Brief antibiotic treatment for an unrelated condition after 6 months
resulted in low urine MMA (median, 2.8 mmol/mol creatinine; range, 1.9-4.8) for the next 7 months.
All concurrent serum MMA concentrations (median, 651 nmol/L; range, 399-919) before and after
month 6 were within the established reference interval (393-1476 nmol/L; n = 48).
Conclusions and Clinical Importance: One milligram of cyano-Cbl daily PO appears efficacious
for maintaining normal clinical status and normal cellular markers of Cbl metabolism in Beagles
with IGS.
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1 | INTRODUCTION
Metabolic derivatives of cobalamin (Cbl), or vitamin B12, act as essen-
tial cofactors of methylmalonyl-CoA mutase, which convert
methylmalonyl-CoA to succinyl-CoA, and methionine synthase, which
is required for the remethylation of homocysteine. A decrease in
Abbreviations: Cbl, cobalamin; IGS, Imerslund-Gräsbeck syndrome; MMA,
methylmalonic acid; IF, intrinsic factor; cubam, functional receptor complex
composed of AMN and CUBN subunits; CUBN, cubilin; AMN, amnionless;
GC-MS, gas chromatography-mass spectrometry; RI, reference interval;
cyano-Cbl, cyanocobalamin; hydroxo-Cbl, hydroxocobalamin; UPLC-TMS,
ultra-performance liquid chromatography-tandem mass spectrometry;
CV, coefficients of variation.
Received: 27 June 2018 Accepted: 13 November 2018
DOI: 10.1111/jvim.15380
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any
medium, provided the original work is properly cited and is not used for commercial purposes.
© 2018 The Authors. Journal of Veterinary Internal Medicine published by Wiley Periodicals, Inc. on behalf of the American College of Veterinary Internal Medicine.
J Vet Intern Med. 2018;1–7. wileyonlinelibrary.com/journal/jvim 1
activity of these intracellular enzymes results in increases in methyl-
malonic acid (MMA) and homocysteine concentrations.1 Dogs are
dependent on intestinal uptake of dietary Cbl bound to intrinsic factor
(IF). The Cbl-IF complex binds to functional receptor complex com-
posed of amnionless (AMN) and cubilin (CUBN) subunits (cubam), a
heteromeric, multiligand, endocytic receptor, consisting of 2 proteins,
AMN and CUBN.2 In people, mutations in either the AMN or CUBN
gene lead to selective Cbl malabsorption known as Imerslund-Gräs-
beck syndrome (IGS).3,4 In dogs, selective intestinal Cbl malabsorption,
comparable to IGS in humans, has been described in Australian
Shepherds,5,6 Beagles,7–13 Border Collies14–17, and Giant Schnau-
zers.18 It is an autosomal recessive trait caused by 2 distinct AMN
mutations in Giant Schnauzers18 and Australian Shepherds, 6 and our
group and others recently identified 2 independent CUBN mutations
in Border Collies19,20 and Beagles.10,21 The condition is lethal in
affected dogs unless detected and treated appropriately.9–11,16,18 Sup-
plementation with adequate amounts of Cbl leads to rapid and com-
plete clinical remission when Cbl is administered sufficiently early in
the course of disease, and the long-term prognosis is excellent with
adequate lifelong treatment.6,8–10,12,13
To date, all reported treatments in dogs have consisted of paren-
teral supplementation to circumvent the underlying cause of the prob-
lem (ie, deficient intestinal uptake of the vitamin). However, sporadic
reports in human medicine indicate that PO supplementation also leads
to normalization of intracellular markers of Cbl deficiency,22,23 and it
was shown that approximately 1% of free Cbl is absorbed along the
entire intestine by passive diffusion without the need for an intact
cubam receptor.24 Although this route of absorption has not been dem-
onstrated in dogs, PO Cbl supplementation recently was determined to
effectively increase serum Cbl concentrations in dogs with chronic
enteropathies and low serum Cbl concentrations.25,26 Our group also
has had positive experiences with PO supplementation in older Beagles
and Border Collies with IGS that could not tolerate repeated IM injec-
tions. These dogs remained clinically healthy and had urine MMA
results within reference intervals (RIs) when evaluated sporadically. We
recently studied the long-term efficacy of monthly and bimonthly
(every 2 months) IM Cbl injections including regular assessment of
MMA as a marker of cellular Cbl availability in 6 juvenile Beagles with
IGS.13 All dogs thrived and were clinically healthy, but the prospect of a
lifelong need for IM injections prompted owners of 3 dogs to try PO
Cbl supplementation. We were able to conduct follow-up assessments
of these dogs, which included regular monitoring of markers of intracel-
lular Cbl availability. We hypothesized that a daily supraphysiologic
PO dose of 1 mg cyano-Cbl would maintain clinical and metabolic
remission in dogs with genetically confirmed IGS.
2 | MATERIALS AND METHODS
2.1 | Animals
The clinical and metabolic health of 3 client-owned purebred Beagles
with IGS was monitored for 13 (n = 2) and 8 (n = 1) months. All dogs
had been diagnosed with IGS using a commercial genetic test (www.
laboklin.de) for the CUBN mutation and initially had received monthly,
followed by bimonthly, IM injections of 1 mg Cbl (VITAMIN B-12
Depot Rotexmedica Injektionslösung) for a period of 15-21 months
before being switched to PO supplementation.13 The age of the dogs
at the time of transition to PO supplementation was 31 (dog 1, male,
neutered) and 29 (n = 2) months. The 2 younger dogs were litter-
mates (male [dog 2] and female [dog 3]). The owners and primary care
veterinarians considered all dogs to be in excellent health at the time
of transition to PO Cbl supplementation.
2.2 | Study design
2.2.1 | Beagles with IGS
Voided urine samples for baseline analysis of MMA concentration
were collected 4 weeks after the last bimonthly Cbl injection (=time
point 0 [t0]) and at monthly intervals (t1, t2, t3, etc.) thereafter. Start-
ing the day after t0, all dogs were given 1 tablet containing 1 mg
cyano-Cbl (B12 Ankermann Wörwag Pharma) PO along with a small
treat, once daily. In dog 1, the concentrations of serum MMA (t1, and
t5-t10) and plasma homocysteine (t1-t3, and t5-t10) were also avail-
able in addition to urine MMA analyses. Additional blood analyses in
dog 1 were done at the owners' request and not because of health
concerns. Serum MMA concentration also was measured once at t7 in
dog 3. The participating primary care veterinarians were asked to cen-
trifuge blood samples for the determination of plasma homocysteine
concentration within 30 minutes. All samples were stored at −20C
for analysis later. The dog owners remained in close contact
(telephone, email) with the first author of this study. Because serum
Cbl concentrations have been shown to be of limited value for the
assessment of Cbl status in supplemented dogs with IGS,13,18 the
decision to include this variable along with urinary MMA concentra-
tion was ultimately left to the discretion of the primary care veterinar-
ian and owner. When included, serum samples for Cbl determination
were collected before PO administration of Cbl that day. All samples
were shipped to our clinic on dry ice using a commercial carrier.
2.3 | Healthy control dogs
In our previous study on parenteral Cbl supplementation, the RI for
urinary MMA concentration was based on urine samples from 28 clini-
cally healthy dogs.13 In the present study, the results of 2 more
healthy dogs with unremarkable laboratory (CBC, serum biochemistry,
urinalysis) results and serum Cbl concentrations within RIs were added
for a total of 30 clinically healthy dogs. Serum samples from 20 healthy
dogs were used for establishing a preliminary RI for serum MMA con-
centrations in our earlier study,13 and we were able to strengthen this
preliminary RI by adding serum MMA results from an additional
28 healthy dogs with unremarkable clinical and laboratory (see above)
evaluations (n = 48).
2.4 | Analyses
Either available serum Cbl concentrations were measured at a com-
mercial veterinary laboratory (www.laboklin.de; n = 1) or samples
were frozen and shipped together with urine samples to our labora-
tory (n = 2). The commercial veterinary laboratory used a
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chemiluminescence assay for Cbl determination, and the RI was
221-590 pmol/L (B12 ECLIA on Cobas 8000 e602). An automated
competitive binding chemiluminescence assay (Immulite 2000, vitamin
B12; Siemens Healthcare Diagnostics) and an RI of 146-721 pmol/L27
were used in our laboratory.
Urine and serum MMA concentrations were analyzed at the
Division of Clinical Chemistry of the University Children's Hospital
Zurich according to accredited methods.28 In brief, the samples were
supplemented with an internal standard, precipitated, and analysis
was done by ultra-performance liquid chromatography-tandem mass
spectrometry (UPLC-TMS) on an Ultimate 3000 XRS UHPLC system
(Dionex; Thermo Scientific) with a SCIEX5500 mass spectrometer
(SCIEX, Framingham, Massachusetts) using multiple reaction monitor-
ing. The lower limit of quantification for this method was 25 nmol/L
in serum and 651 nmol/L in urine. Results for urine MMA were
expressed as mmol MMA per mol creatinine. Creatinine concentra-
tions were determined using a kinetic Jaffe method on a DxC600
clinical chemistry analyzer (Beckman Coulter International S.A., Nyon,
Switzerland) using commercial reagents. The inter-assay coefficients
of variation (CV) of the analyses were 5.8% for MMA in serum and
urine and 2.7% for creatinine in urine.
Plasma homocysteine concentration was measured in the same
laboratory using a commercial Axis-Shield enzymatic homocysteine
assay (Axis-Shield Diagnostics Ltd., Dundee, Scotland) on a DxC600
chemistry analyzer (Beckman Coulter International S.A.) with an inter-
assay CV of 3.2%.
2.5 | Statistical analysis
Data were tested for normal distribution using D'Agostino and
Pearson omnibus tests. Urine MMA results of healthy dogs are pre-
sented as range and median values. The RI for serum MMA concentra-
tion was calculated using the 5th and 95th percentiles.
3 | RESULTS
3.1 | Healthy control dogs
Urinary MMA concentrations were not normally distributed in
30 healthy control dogs and ranged from 1.3 to 76.5 mmol/mol creat-
inine (median, 2.9 mmol/mol creatinine). Serum MMA concentrations
in 48 healthy dogs ranged from 311 to 1740 nmol/L (median,
585 nmol/L). The RI was established as 393 nmol/L (90% confidence
interval [CI], 325-400 nmol/L) to 1476 nmol/L (90% CI, 1136-
2216 nmol/L) .
3.2 | Response to daily oral cyano-Cbl
supplementation
3.2.1 | Clinical signs
Dogs received daily PO cyano-Cbl supplementation for a median of
9 (range, 8-13) months. All dogs were considered free of clinical signs
and described as active and alert by owners and veterinarians while
receiving daily PO cyano-Cbl supplementation. Two dogs (dogs 1 and
3) were considered to be athletic based on appearance and activity
level. Dog 1 (Figure 1, red squares) was treated for a bacterial skin
infection with a 10-day course of cephalexin (Rilexine; Virbac S.A.,
Carros, France) and amoxicillin (Kesium, Biokema SA, Crissier,
Switzerland) starting 2 days after urine sampling at t6. No other drugs
were given during the study period except routine administration of
anthelmintics. The results of periodic hematologic evaluations under-
taken by the primary care veterinarians were unremarkable in all dogs.
3.3 | Serum Cbl concentration
Sporadically evaluated serum Cbl concentrations were within RIs. In
dog 1 (Figure 1, red squares), serum Cbl concentration was measured
at t6 (512 pmol/L). In dog 2 (Figure 1, purple triangles), serum Cbl
concentration was measured at t7 (758 pmol/L), and in dog 3 (Figure 1,
orange triangles), serum Cbl concentration was 633 pmol/L at t3.
3.4 | Urinary MMA concentrations
Thirty-four urinary MMA results were available from dogs receiving
PO cyano-Cbl supplementation. All urine MMA concentrations from
dogs 2 and 3 remained in the low-normal range (median, 2.5 mmol/
mol creatinine; range, 1.2-9 mmol/mol creatinine). This result was
comparable to previously recorded urine MMA concentrations in dogs
receiving monthly and bimonthly Cbl injections.13 Dog 1 continued to
excrete higher amounts of MMA in urine for an additional 6 months,
which was also similar to previous results in this dog when treated
with IM injections (Figure 1). However, at t7 when the prescribed
course of antibiotics had been finished, urine MMA concentrations
had decreased into the range of dogs 2 and 3 and remained in that
range (1.9-4.8 mmol/mol creatinine) for the next 7 months (Figure 1).
3.5 | Serum MMA concentrations
In dog 1, serum MMA concentrations were measured at t1 and from
t5 to t10. All 7 results were within the RI and ranged from 399 to
919 nmol/L (median, 651 nmol/L; RI, 393-1476 nmol/L). Serum
MMA concentration also was measured in dog 3 at t7 and was
642 nmol/L (RI, 393-1476 nmol/L).
3.6 | Plasma homocysteine concentrations
In dog 1, plasma homocysteine concentrations at t1-t3 were 21.5,
18.8, and 27.4 μmol/L, respectively, and they ranged from 15 to
23.8 μmol/L (median, 17.7 μmol/L) between t5 and t10.
4 | DISCUSSION
The results of our study indicate that daily PO administration of 1 mg
cyano-Cbl represents an efficacious regimen for maintaining normal
health status as well as unremarkable cellular Cbl status based on
urine and serum MMA concentrations in Beagles with IGS. Compared
to our previous study evaluating parenteral Cbl supplementation in
IGS dogs,13 we herein report a more robust serum MMA RI
(393-1476 nmol/L) based on 48 healthy dogs, which compares
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favorably to what has been published recently using similar methodol-
ogy in 43 healthy dogs (414.7-1192.5 nmol/L).29
Daily PO cyano-Cbl supplementation recently has been shown to
effectively increase serum Cbl concentrations in dogs with
enteropathy-associated low-normal and subnormal serum Cbl concen-
trations.25,26 It was speculated that dogs have an alternative pathway
for Cbl absorption, similar to that demonstrated in studies involving
radioactively labeled Cbl in humans.24 However, it was not possible
with that study design to determine whether dogs with chronic enter-
opathy had a total or only partial lack of active cubam receptor-
mediated absorption of Cbl and to establish the extent of passive
absorption by diffusion that led to normalization of serum Cbl concen-
tration. A factor that may have aided Cbl absorption via active recep-
tors was that all dogs with chronic enteropathy received treatment for
their underlying intestinal disease.25,26 The results of our study using
IGS-affected dogs with a known functional defect of cubam but oth-
erwise healthy intestinal tract indicate for the first time that passive
intestinal Cbl absorption alone leads to a normal clinical and cellular
Cbl status in dogs. This is especially true for the Beagle breed because
a recent study showed that CUBN expression was undetectable in tis-
sue samples from an affected dog,10 whereas in Border Collies with
IGS, expression of small amounts of residual CUBN retaining IF-Cbl
binding recently was reported.20 However, this laboratory finding
does not appear to be associated with effective Cbl absorption
because all available publications concerning Border Collies with IGS
have reported the presence of severe Cbl deficiency.14–17
Cobalamin deficiency has been associated with changes in perme-
ability, absorptive function, and histologic appearance of the intestinal
mucosa in humans, and mucosal structure and function normalized in
these patients after parenteral Cbl treatment.30 Similar effects on the
intestinal tract frequently have been discussed in dogs with Cbl defi-
ciency. In the present study, all dogs entered the PO supplementation
phase after having been supplemented parenterally for an extended
period of time (15, 19, and 21 months). We therefore can confidently
rule out possible negative effects of preexisting Cbl deficiency on
intestinal absorptive capacity.
FIGURE 1 Light-blue shaded area: Urinary methylmalonic acid (MMA) concentrations (mmol/mol creatinine) from voided urine samples in 3 dogs
with IGS during monthly, and bimonthly (*) supplementation with 1 mg OH-Cbl, administered IM (J Vet Intern Med 2018;32 (3):1033-1040).
Collection of voided urine samples was continued at monthly intervals for the evaluation of PO Cbl supplementation. Baseline urine MMA
concentrations at t0 PO again represent the preceding urine MMA concentration recorded 4 weeks after the last Cbl injection (identical values
connected with dark-blue solid line). Starting the day after t0 PO, all dogs were given 1 tablet containing 1 mg cyano-Cbl orally, once daily.
Additional x signs represent the concurrent documentation of normal serum MMA concentration (RI: 393-1476 nmol/L). Please note that dog
1 (pink squares) was treated for an unrelated bacterial skin infection with a 10-day course of cephalexin and amoxicillin starting 2 days after urine
sampling at t6
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We used a dose of 1 mg cyano-Cbl daily in dogs that weighed
approximately 11 kg, which differed from previous studies in which
the dose varied from 0.25 to 1 mg cyano-Cbl, depending on body
weight.25,26 The dogs in our study were known to suffer from com-
plete lack of Cbl absorption in contrast to dogs with enteropathy-
associated hypocobalaminemia, and therefore we chose to use a
whole tablet (1 mg) per day rather than dividing a tablet. Moreover,
experience with a number of older Beagles and Border Collies with
IGS from our clinic caseload has shown that this dose works well. In
addition, our approach precluded issues with accurate dosing because
the manufacturer's recommendation was not to divide coated tablets.
Lastly, adverse effects related to high PO doses of Cbl have not been
reported. We generally prefer hydroxo-Cbl for parenteral Cbl supple-
mentation in our hospital because it is the natural form of Cbl and
considered the treatment of choice for children with IGS.4,31–33 More-
over, early studies in dogs showed that hydroxo-Cbl produces more
prolonged increases in serum Cbl concentrations when injected IM
than injection of equal amounts of cyano-Cbl.34 In addition, compared
to cyano-Cbl, it has been shown that hydroxo-Cbl has increased liver
uptake and less rapid urinary excretion in humans.35 For these rea-
sons, we had also used hydroxo-Cbl in our previous study on the effi-
cacy of parenteral Cbl supplementation in Beagles with IGS.13
However, at the time of the present study, cyano-Cbl was the only
available PO Cbl product in Switzerland.
Although hundreds of IGS cases have been published worldwide
in human medicine, only 3 articles36–38 have examined the efficacy of
PO Cbl supplementation and only 1 article specifically assessed the
effect of PO treatment on cellular Cbl status in people.36 Biweekly PO
treatment with 1 mg cyano-Cbl appeared to be a successful mainte-
nance regimen in 14 children with IGS based on clinical signs, hemato-
logic evaluations, and serum Cbl concentrations,37 whereas 1 mg
cyano-Cbl daily for 7 days every month maintained normal clinical
health in a teenager with IGS who was monitored for >5 years.38
However, some abnormalities were identified when cellular Cbl status
was assessed in a more recent study. Biweekly PO treatment with
1 mg cyano-Cbl for >5 years resulted in unremarkable hematologic
results but did not correct all other markers of Cbl deficiency.36
Twenty-five percent of patients with congenital Cbl deficiency still
had increased concentrations of MMA (n = 4) and homocysteine
(n = 1) but unexpectedly had Cbl concentrations within RI, which
resulted in discussion of the adequacy of hematologic variables and
Cbl concentrations as measures of Cbl status.36 We also were inter-
ested in exploring less intense dosing schedules for our patients, but
when owners were asked whether they would consider every-other-
day administration of PO Cbl, they declined. Reasons for a lack of
interest included the low cost of the PO Cbl product and the impracti-
cability of every-other-day dosing.
We did not measure serum Cbl concentrations routinely because
long-term experience has shown that low or even undetectable serum
Cbl concentrations often are encountered in clinically healthy Border
Collies and Beagles that have received parenteral treatment for
IGS.13,16 This finding also has been reported in clinically healthy Bor-
der Collies, Beagles, and Giant Schnauzers that were receiving long-
term Cbl supplementation for IGS.7,13,15,16,18 The results of our previ-
ous study on parenteral Cbl supplementation supported this finding
with the majority of serum Cbl concentrations (22 of 24 samples)
being below the RI (11) or even undetectable (11) in the face of low
MMA concentrations.13 We speculated that the half-life of Cbl bound
intracellularly as a coenzyme is longer than the residence time of Cbl
in the circulation, which would mean that Cbl continues to be active
in tissues and Cbl-dependent metabolism remains normal even when
serum concentrations are low. Interestingly, the few available serum
Cbl concentrations in this study were all within RI, similar to what has
been published recently.25,26
Urine MMA results from dog 1 stood out insofar as they initially
remained higher than those of dogs 2 and 3. Urine MMA concentra-
tions at t1-t6 were in agreement with those of a previous study when
Dog 1 was treated with monthly and bimonthly parenteral Cbl supple-
mentation (Figure 1).13 In contrast, concurrent evaluation of serum
MMA concentrations (t1, t5-t10) showed that all results were within
the RI (Figure 1), a finding that had also been previously noted in this
dog during parenteral (bimonthly) Cbl supplementation.13 At that time,
we had speculated that bacterial biosynthesis of MMA contributed to
the mild increases in urine MMA excretion in dog 1 because several
species of bacteria can synthesize MMA and all urine samples were
voided samples.39,40 With regard to this hypothesis, it is important to
note that in dog 1, antibiotic treatment for a bacterial skin infection
resulted in an abrupt and persistent decrease in urine MMA concen-
tration. The urine MMA concentration decreased after the prescribed
course of antibiotics at t7 and remained in the range recorded for the
other dogs receiving PO and parenteral supplementation13 for the
next 6 months. Our hypothesis cannot be validated without urine cul-
ture results. However, it seems likely that the higher urine MMA con-
centrations measured in dog 1 in the present and previous studies
were caused by bacterial MMA synthesis, especially when one con-
siders that there were no other plausible reasons for a sudden
decrease.
Similar to serum MMA concentrations, results of concurrently
measured plasma homocysteine concentration in dog 1 indicated ade-
quate Cbl supplementation when compared to published RIs.41 We
had previously been working with a homocysteine RI of
4.3-18.4 μmol/L that was established using HPLC and fluorometric
detection in 35 dogs.27 Because of laboratory and methodology
changes, we currently do not have an in-house homocysteine RI. A
homocysteine RI of 5-22.1 μmol/L recently was established using a
gas chromatography-mass spectrometry (GC-MS) method in
35 healthy dogs.41 Most homocysteine concentrations in dog 1 were
within this RI, whereas 2 of 9 measurements, over the 13-month
period of PO supplementation were minimally higher. In this regard,
we cannot fully eliminate pre-analytical factors, such as the time
between blood sampling and centrifugation and separation of plasma,
as a cause of increased homocysteine concentrations. In humans with
IGS, normalization of homocysteine concentrations could be achieved
with biweekly PO cyano-Cbl (1 mg) treatment.36 In dogs with IGS,
very little is known about homocysteine as a marker for disease moni-
toring. Although hyperhomocysteinemia has been reported in dogs
with IGS with markedly depleted cellular Cbl stores before
treatment,9,16 normalization of homocysteine concentrations has only
been reported once in a Beagle that was treated with IM (0.25 mg)
Cbl supplementation biweekly9 and once in a Giant Schnauzer
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4 weeks after IM (1 mg) Cbl supplementation.18 Clearly, the value of
homocysteine as a therapeutic marker in dogs with IGS requires fur-
ther study.
The main limitation of our study is the small number of dogs;
however, we were dependent on the willingness of pet owners to
cooperate. We are working with several Border Collies and Beagles
with IGS that are doing very well clinically with daily PO Cbl supple-
mentation but unfortunately do not have a complete data set to pub-
lish these cases. The situation is similar in humans when considering
the ratio of treatment studies36,38 to disease prevalence of IGS.
In conclusion, a maintenance dose of 1 mg cyano-Cbl adminis-
tered PO appears efficacious for maintaining normal clinical status
and cellular markers of Cbl metabolism in dogs with IGS caused by a
mutation in the CUBN gene. Our findings further corroborate the
hypothesis that an alternative absorptive pathway of Cbl absorption
exists in dogs. We assume that comparable results can be achieved
when treating other breeds of dogs with IGS caused by different
mutations, but this warrants further study.
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